Last updated: March 1, 2026
What is NDC 70069-0271?
NDC 70069-0271 refers to Amphotericin B Liposomal (brand: Ambisome), an antifungal agent used to treat invasive fungal infections. It is produced by Gilead Sciences and primarily utilized in hospital settings for serious infections such as cryptococcal meningitis, aspergillosis, and candidiasis.
Market landscape
Global demand and distribution
The worldwide antifungal market stood at approximately $5.2 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.2% through 2027.
Liposomal Amphotericin B accounts for an estimated 25% of the antifungal injectable segment. The rising prevalence of immunocompromised conditions (HIV/AIDS, cancer, organ transplants) propels demand. Hospitals and infusion centers dominate purchase channels.
Key market factors
- Treatment prevalence: An estimated 2 million invasive fungal infection cases annually globally.
- Healthcare cost pressures: Hospitals seek cost-effective, high-efficacy treatments, favoring liposomal formulations over traditional amphotericin B due to lower toxicity.
- Regulatory environment: The drug holds full approval in major markets (FDA, EMA). Pending approvals in developing countries expand markets.
Competitive landscape
- Main competitors: Fungizone (amphotericin B deoxycholate), ABELcet, Ambisome.
- Patent status: Gilead holds an extensive patent portfolio through 2028, limiting biosimilar entrants.
- Pricing influence: Cost per vial differs significantly; Ambisome averages $2,800–$3,200 in the U.S.
Price analysis
Historical pricing trends
| Year |
Average Price per Vial |
Notes |
| 2018 |
$2,900 |
Stable, with slight fluctuations |
| 2020 |
$3,000 |
Slight increases amid inflation |
| 2022 |
$3,200 |
Price hike linked to supply chain challenges |
Factors affecting current and future pricing
- Manufacturing costs: Escalation due to complex liposomal formulation processes.
- Market exclusivity: Patent protections support premium pricing until 2028.
- Reimbursement policies: Payers increasingly scrutinize high-cost antifungals; rebate negotiations impact net price.
Projected price trajectory (2023–2028)
| Year |
Estimated Price per Vial |
Change from Previous Year |
Underlying Factors |
| 2023 |
$3,200 |
0% |
Stabilization post supply chain disruptions |
| 2024 |
$3,300 |
3.1% |
Anticipated patent protection influence |
| 2025 |
$3,350 |
1.5% |
Cost inflation, potential slight market expansion |
| 2026 |
$3,400 |
1.5% |
Patent expiry close; biosimilar competition unlikely yet |
| 2027 |
$3,450 |
1.5% |
Patent expiry approaches; patent cliff risk mounts |
Revenue impact forecast
Based on estimated sales volume of 10,000 vials annually in the U.S.:
| Year |
Revenue (USD millions) |
Growth Rate |
Notes |
| 2022 |
$32 million |
— |
Baseline |
| 2023 |
$32 million |
0% |
Supply chain stabilized, stable price |
| 2024 |
$33 million |
3.1% |
Price increase, steady demand |
| 2025 |
$34 million |
3% |
Slight growth, moderate market expansion |
| 2026 |
$34.5 million |
1.5% |
Patent expiry approaches |
Risks and uncertainties
- Patent expiration: Biosimilar entry post-2028 could reduce prices.
- Regulatory changes: Reimbursement and approval shifts may impact sales.
- Manufacturing disruptions: Liposomal formulation complexity raises supply risks.
- Market competition: New antifungal agents emerging with better efficacy or lower costs might erode market share.
Key Takeaways
- NDC 70069-0271 (Ambisome) operates in a high-value antifungal market growing steadily at around 6% CAGR.
- Current average price per vial is approximately $3,200, with projection increases of 1.5% annually until patent expiry in 2028.
- The market's growth depends heavily on fungal infection prevalence and hospital adoption.
- Patent protection secures premium pricing until 2028; biosimilar competition is unlikely before then.
- Cost pressures, regulatory changes, and biosimilar entry present potential downward pressures post-2028.
FAQs
1. When will biosimilar versions of Amphotericin B Liposomal likely enter the market?
Biosimilars in the U.S. are unlikely before patent expiry in 2028; regulatory and patent challenges delay entry.
2. How does the price of Ambisome compare to older forms like Fungizone?
Ambisome averages $3,200 per vial, whereas Fungizone costs around $100–$200 per vial but has higher toxicity, limiting its use.
3. What is the primary driver of demand for amphotericin B liposomal?
The increase in immunocompromised patient populations drives demand for safer, more effective antifungals.
4. How might patent expiration affect market dynamics?
Post-2028, biosimilars could reduce prices by 30–50%, impacting revenue and market share.
5. What opportunities exist for new formulations or delivery methods?
Development of less costly or oral equivalents and improved delivery systems remain ongoing, but none currently threaten Ambisome’s market dominance before patent expiry.
References:
[1] MarketsandMarkets. (2022). Antifungal Market – Global Forecast to 2027.
[2] Bloomberg Intelligence. (2023). Healthcare Product Pricing Trends.
[3] FDA. (2022). Amphotericin B Liposomal (Ambisome) Approved Indications.
[4] Gilead Sciences. (2023). Annual Financial Report.
[5] IQVIA. (2022). Hospital Drug Utilization Data.
